# NeoSTAR (NCT04230109)

> Sacituzumab Govitecan In TNBC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04230109
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Massachusetts General Hospital
- Conditions: Invasive Breast Cancer; Triple Negative Breast Cancer; ER-Negative Breast Cancer; PR-Negative Breast Cancer; HER2-negative Breast Cancer
- Interventions: Sacituzumab Govitecan; Pembrolizumab
- Enrollment: 239
- Primary outcome: Pathological complete response(pCR) rate with sacituzumab govitecan

## Commentary we found

- X threads: 33
- Podcasts: 27
- YouTube: 21
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=neostar-nct04230109

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04230109", "email": "<work email>"}; the inbox owner confirms by the emailed link.